# Bronchogen

> Synthetic Ala-Asp-Glu-Leu tetrapeptide studied as a respiratory-tissue bioregulator.

- Also known as: Ala-Asp-Glu-Leu, ADEL tetrapeptide
- Class: Immune, Bioregulators
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/bronchogen

## Overview

Bronchogen is a synthetic tetrapeptide (Ala-Asp-Glu-Leu) in the Khavinson short-peptide bioregulator series, studied for effects on bronchial and respiratory-tract tissue.

Bronchogen (Ala-Asp-Glu-Leu) is the respiratory-directed member of the defined short-peptide bioregulator family, studied in the context of chronic bronchopulmonary conditions in the originating research tradition.

Reported work examined bronchial epithelial markers and inflammatory indices in respiratory models, consistent with the class hypothesis of tissue-selective transcriptional modulation. Evidence is concentrated in one research tradition with limited independent replication, and it is not FDA-approved.

## Mechanism

Proposed gene-regulatory modulation of bronchial epithelial gene expression.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular weight | 446.5 Da |

## Sequence

```
ADEL
```

## Research areas

Studied in: Respiratory biology, Immune modulation, Peptide bioregulators.

Guides on this site:

- [Immune & Inflammation](https://www.americanpeptide.com/research-areas/immune-inflammation): Thymic and host-defense peptides studied for immune modulation.
- [Peptide Bioregulators](https://www.americanpeptide.com/research-areas/bioregulators): Short, tissue-specific peptides proposed to regulate gene expression — the Khavinson series.

## Key research

- Respiratory focus — studied for effects on bronchial epithelium and inflammatory markers in models of chronic respiratory disease.
- Class mechanism — proposed short peptide–DNA interaction driving tissue-selective gene expression.
- Evidence quality — single-tradition and largely preclinical; preliminary.

## FAQs

### What is Bronchogen?

Bronchogen is a synthetic Ala-Asp-Glu-Leu tetrapeptide studied as a respiratory-tissue bioregulator in the Khavinson short-peptide series.

### What tissue is it associated with?

The bronchi and respiratory-tract epithelium — each bioregulator in the series is framed around a specific target tissue.

### How strong is the evidence?

It is concentrated in a single research tradition and is largely preclinical, so findings are preliminary. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning Bronchogen, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Airway Epithelium Gene Expression: AEGIS IDE](https://clinicaltrials.gov/study/NCT00746759) — COMPLETED · NCT00746759

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/bronchogen
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.